Reference
Singh AM, et al. Safety Monitoring Activity during EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients with Lung Cancer. JCO Oncology Practice 19 : 345-351, No. 6, Jun 2023. Available from: URL: http://doi.org/10.1200/OP.22.00787
Rights and permissions
About this article
Cite this article
Alectinib/lorlatinib/osimertinib. Reactions Weekly 1975, 19 (2023). https://doi.org/10.1007/s40278-023-46374-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-46374-4